Compare Amylx Pharmaceuticals Inc (AMLX) vs Godaddy Inc (GDDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Godaddy Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.86 (market cap $2.64B), while Godaddy Inc trades at $90.64 (market cap $11.49B). The key difference: Godaddy Inc is far larger — about 4.4× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Godaddy Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | GDDY | |
|---|---|---|
Market Cap | $2.64B | $11.49B |
Sector | Health | Technology |
52-Week High | $24.19 | $148.88 |
52-Week Low | $7.82 | $75.07 |
Enterprise Value | $2.39B | $14.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
GoDaddy (GDDY) trades at $91.49, up 0.46% today, with a neutral technical signal and strong fundamentals including a 17.83% net income margin and consistent earnings beats. Revenue growth is steady, projected at $5.1B for 2026, while recent news highlights legal investigations into potential securities violations, creating investor uncertainty.
The stock offers value with a P/E of 13.48 and a consensus price target of $112.13, but risks include ongoing legal scrutiny and high debt levels. Analyst sentiment remains bullish with 57% buy ratings, though technical indicators suggest near-term consolidation around key support at $90.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Godaddy Inc
GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.
Read more on GDDY →
